Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Public ClinicalTrials.gov record NCT06957691. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT Trial)
Study identification
- NCT ID
- NCT06957691
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Shehzad Basaria, M.D.
- Other
- Enrollment
- 60 participants
Conditions and interventions
Conditions
- Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma
- Androgen Deprivation Therapy
- Androgen-deprivation Therapy
- Hot Flashes
- Hot Flushes
- Hot Flushes and/or Sweats
- Prostate Adenocarcinoma
- Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
- Prostate Cancer Metastatic Disease
- Prostate Cancer Recurrent
- Prostate Cancer With Bone Metastasis
- Prostate Carcinoma
- Prostate Neoplasm
- Vasomotor Disturbance
- Vasomotor Symptoms
- Vasomotor Symptoms (VMS)
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Vasomotor Symptoms; Hot Flashes
Interventions
- Placebo Drug
- fezolinetant - reference formulation Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2026
- Primary completion
- Aug 30, 2028
- Completion
- Dec 30, 2028
- Last update posted
- Mar 8, 2026
2026 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06957691, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06957691 live on ClinicalTrials.gov.